NextCure Doses First Patient in Phase 1 Study of LNCB74, a Promising Cancer Therapy

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-c...

January 13, 2025 | Monday | News
Veralox Therapeutics Acquires Nudge Therapeutics to Advance Preclinical cGAS Inhibitor Compounds

 Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, anno...

January 10, 2025 | Friday | News
Grifols Submits Biologics License Application for New Fibrinogen Treatment to FDA

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has submitted a B...

January 10, 2025 | Friday | News
Exelixis Announces FDA Update on sNDA for CABOMETYX® in Advanced pNET and epNET

 Exelixis, Inc. (Nasdaq: EXEL) announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New ...

January 10, 2025 | Friday | News
Xentria Expands Global Clinical Trials and Biosimilar Portfolio in 2025

Xentria, Inc., a clinical-stage biotherapeutics company focused on developing therapeutics to address unmet medical needs, announced operational expansion ...

January 09, 2025 | Thursday | News
FDA Accepts Revised sNDA for Astellas' IZERVAY™ in Treatment of Geographic Atrophy

 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced the U.S. Food and Drug Administration (FDA) a...

January 09, 2025 | Thursday | News
Agios Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for PYRUKYND® in Thalassemia Treatment

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...

January 09, 2025 | Thursday | News
Eyebright Medical’s Loong Crystal PR Intraocular Lens Receives NMPA Class III Medical Device Certification

Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collective...

January 08, 2025 | Wednesday | News
Positive SIRONA Study Results Highlight Sirolimus-Coated Balloons as Effective Alternative to Paclitaxel for PAD Treatment

Concept Medical Inc., a global leader in innovative drug delivery technologies, is proud to report positive results from the SIRONA (Head-to-Head...

January 08, 2025 | Wednesday | News
Rise Therapeutics Completes Dose Escalation for R-2487 and R-3750, Advancing to Dose Expansion in Clinical Trials

Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines,  announced that it has completed dose esc...

January 07, 2025 | Tuesday | News
Adcentrx Doses First Patient in Phase 1a/b Study of ADRX-0405 for Advanced Solid Tumors

 Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-thr...

January 07, 2025 | Tuesday | News
Jacobio Pharma's KRAS G12C Inhibitor Glecirasib Data Published in Nature Medicine, Showcasing Impressive Efficacy in NSCLC

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced that the data from a registrational clinical trial of...

January 07, 2025 | Tuesday | News
LPOXY Therapeutics to Acquire Key Assets from Xeno Biosciences to Advance C. difficile Infection Prevention Therapy

LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease prevention, announced...

January 06, 2025 | Monday | News
GSK's Nucala (Mepolizumab) Approved in China for Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

GSK plc (LSE/NYSE: GSK) announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibod...

January 06, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close